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龄年轻化。大量的流行病学调查和实验研究证明 , 高血脂、高血压、吸烟 、
糖尿病等都是与 As 发生相关的危险因素，但关于 As 发生的机制一直众说纷





随后的研究发现，OEA 能抑制脂多糖诱导的 THP-1 细胞的炎症反应。OEA 减
少 ox-LDL 诱导的人脐静脉内皮细胞的坏死，促进人脐静脉内皮细胞上 PPAR-α
受体 mRNA 表达的上调，还具有抑制小鼠巨噬细胞（RAW264.7）C-反应蛋白、




目的：研究 OEA 对 TNF-α 诱导的人脐静脉内皮细胞炎症反应的保护性作
用及 OEA 发挥作用的相关机制。 
方法：原代提取培养人脐静脉内皮细胞，给予不同浓度的 OEA 预保护处
理，然后予 TNF-α 刺激诱导内皮细胞炎症反应，利用酶联免疫吸附试验、
Real-time RT PCR、Western blotting 等实验技术检测 IL-6、IL-8、VCAM-1、
ICAM-1 等炎症因子及黏附分子的表达。在同样的处理条件下，分别给予
PPAR-α 和 CB2 受体阻断剂，检测 IL-6、IL-8、VCAM-1、ICAM-1 表达的变化，
并进一步探讨 OEA 发挥抗炎及抗动脉粥样硬化作用的机制。 
结果：OEA 呈浓度依赖性降低 TNF-α 诱导的 HUVECs 中 IL-6、IL-8、














PPAR-α 和 CB2 受体后，OEA 降低 IL-6、IL-8、VCAM-1、ICAM-1 表达的效
应减弱。不同浓度的 OEA 能激活 PPAR-α 和 CB2 受体，降低炎症信号通路分子 
NF-κB P65 的表达，且阻断 PPAR-α 和 CB2 受体后，对 NF-κB P65 抑制作用减
弱。另外，不同浓度的 OEA 对 P38 MAPK 和 p-STAT3 等炎症信号分子也有较
强的作用。 
结论：OEA 对 TNF-α 诱导的 HUVECs 炎症反应有保护性作用，能够明显
降低相关炎症因子及黏附分子的表达。OEA 的抗炎及抗 As 作用和 PPAR-α 和
CB2 受体密切相关，这对进一步研究 OEA 作为一种新的预防及治疗 As 有一定
的指导意义。 
























Background: Atherosclerosis （ As ） is a multi-factor diseAse which is 
originating in the arterial wall. The morbidity and mortality of As is rising year by 
year at present and the onset age tend to be younger. A large number of 
epidemiological and experimental research showed that hypertension, smoking, 
diabetes, hyperlipidemia are related to As, however, the mechanism of As is unclear. 
Until 1999, ROSS et al came up with the idea “As is a chronic inflammatory 
diseAse” which brought us a novel direction. This study is based on this argument to 
find a new and low side effect medicine. OEA is a kind of endogenous grease which 
find in the research of obesity. It is a natural agonist of PPAR-α. Subsequently 
researches find that OEA inhibits the THP-1 inflammation induced by LPS. OEA 
decreases the necrosis of HUVECs induced by ox-LDL and up-regulation the 
PPAR-α mRNA expression.Meanwhile, OEA reduces the c-reaction protein and 
TNF-α secretion in mouse macrophages (RAW264.7). Previous studies from our lab 
show that OEA has a good protective effect in TNF-α induced damages and 
inflammation in HUVECs.Whereas the mechanism of OEA is still unknown. 
Therefore this study is to illuminate the effects of OEA and the potential mechanism. 
Aim: To study the role of OEA in the inflammation of human umbilical vein 
endothelial cells (HUVECs) induced by tumor necrosis factor-α (TNF-α) and 
identify the mechanisms of OEA’s function. 
Methods: Primary cultured HUVECs pre-treated with different concentration 
of OEA, using TNF-α to stimulate an inflammatory response subsequently. 
Enzyme-linked immunosorbent Assay, real-time RT-PCR, Western blotting are 
applied to detect the change of  IL-6、IL-8、VCAM-1、ICAM-1. Under the same 
condition, pre-treated with antagonists of PPAR-α and CB2 respectively, then tests 
the change of IL-6、IL-8、VCAM-1、ICAM-1 to demonstrate the underlying 
mechanism of OEA’s anti-inflammation effect. 














IL8.Meanwhile OEA enhanced the PPAR-α and CB2 which this effect is more 
obviously at a concentration of 100μM. OEA inhibits the nuclear factor-κB (NF-κB) 
pathways. Finally, when pre-treated with a PPAR-α and CB2 antagonist, the effect of 
OEA on NF-κB was partly abolished. In addition to this, OEA also has an influence 
on P38 MAPK and STAT3 singal molecular. 
Conclusion: OEA attenuates the TNF-α-induced inflammation in HUVECs 
through its effect on PPAR-α and CB2, further more inhibits the activation of NF-κB. 
These results imply that OEA has a good anti-inflammation effect on HUVECs.  
Keywords: OEA; Inflammation; peroxisome proliferator-activated receptors -α; 
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